Less than two years after taking the reins from founding chief Rusty Williams, Five Prime Therapeutics CEO Aron Knickerbocker is exiting the company. Knickerbocker, who had been the chief ...

"With the addition of Aron Knickerbocker as CEO, we are building a world-class organization with deep experience in bringing breakthrough medicines to cancer patients. Aron's record of ...

Five Prime Therapeutics, Inc. (FPRX) Q2 2018 Earnings Conference Call August 8, 2018 4:30 PM ETExecutivesHeather Rowe - Senior Director of Investor ...

today announced that Aron Knickerbocker, Chief Executive Officer, will present at the Leerink Partners Roundtable Series: Rare Disease & Oncology, Oct. 3, 2018, at 10:30 am ET. The presentation ...

Five Prime Therapeutics has tapped into its existing management to replace current president and CEO Rusty Williams, with chief operating officer Aron Knickerbocker lined up to take the helm early ...

today announced that Aron Knickerbocker, Chief Executive Officer, will present at the Goldman Sachs 39th Annual Global Healthcare Conference, June 14, 2018, at 8:00 am PT. The presentation will be ...

as it accentuates our confidence in AU-007 as a potential best-in-class therapeutic for multiple cancers," said Aron Knickerbocker, Aulos Bioscience’s president and chief executive officer.

"We are excited that the first patient is receiving treatment in this new Phase 2 cohort evaluating AU-007 in combination with nivolumab," said Aron Knickerbocker, Aulos Bioscience’s president ...